Changes to Executive Board of Carl Zeiss AG
- Dr. Ludwin Monz, Head of the ZEISS Medical Technology segment, will be stepping down from his position as President and CEO of the Executive Board of Carl Zeiss Meditec AG at his own request and by amicable agreement on 31 December 2021.
- He will be succeeded by Dr. Markus Weber effective 1 January 2022. Dr. Weber is currently a member of the Executive Board of Carl Zeiss AG and is responsible for the ZEISS Semiconductor Manufacturing Technology segment.
- Effective 1 January 2022, Mr. Andreas Pecher will become the new Head of the ZEISS Semiconductor Manufacturing Technology segment and Executive Board member of Carl Zeiss AG. Mr. Pecher is currently Head of the Semiconductor Manufacturing Optics strategic business unit.
President and CEO of Carl Zeiss Meditec AG, Dr. Ludwin Monz, has announced to the Supervisory Board that he will not be accepting another term in office. The Supervisory Board notes his decision with regret. Dr. Monz and the Supervisory Board have agreed to end his term on 31 December 2021. Dr. Monz is currently responsible for the ZEISS Medical Technology segment. He is also President and CEO of the listed company Carl Zeiss Meditec AG. He will be bowing out of this role as well.
Effective 1 January 2022, the Supervisory Board will be transferring his duties at the ZEISS Medical Technology segment to Dr. Markus Weber. Dr. Weber is currently responsible for the ZEISS Semiconductor Manufacturing Technology segment and will relinquish his current duties on 31 December 2021.
The Supervisory Board has appointed Mr. Andreas Pecher to take over from Dr. Weber as Head of the ZEISS Semiconductor Manufacturing Technology segment and Executive Board member of Carl Zeiss AG. Mr. Pecher is currently Head of the Semiconductor Manufacturing Optics (SMO) strategic business unit. His successor at SMO will be announced in the coming weeks.
"The Supervisory Board of Carl Zeiss AG would like to thank Dr. Monz for his outstanding commitment and the incredible success he has had in advancing the ZEISS Medical Technology segment," said Dr. Dieter Kurz, Chairman of the Supervisory Board of Carl Zeiss AG. "We were saddened to hear of Dr. Monz' decision not to stand for another term, but we do wish him all the best going forward."
Dr. Monz also thanked the Supervisory Board for its trusting collaboration: "I would like to thank the Supervisory Board for its exceptional support over the years. Furthermore, I would also like to wish my successor Dr. Markus Weber all the best going forward."
When it comes to making personnel decisions, the Supervisory Board of Carl Zeiss AG strives to ensure continuity on the Executive Board team. The Supervisory Board is delighted to have found suitable successors in Dr. Weber and Mr. Pecher from the ZEISS Group's own ranks and wishes them both all the best going forward.
"Dr. Weber has become familiar with the company from a variety of perspectives. Most recently, he once again leveraged his extensive expertise and leadership skills as Head of the Semiconductor Manufacturing Technology segment to great success," said Dr. Kurz. "At his disposal he has both exceptional innovation management acumen and a management philosophy based on a solid foundation made up of values and culture." As Executive Board member of Carl Zeiss AG, Dr. Weber's current responsibilities include the Semiconductor Manufacturing Technology segment, the Shared Production Unit of the ZEISS Group and the Korea sales region.
Dr. Weber will be succeeded as Head of the Semiconductor Manufacturing Technology segment by Mr. Andreas Pecher. "The Supervisory Board is delighted to have found a semiconductor technology expert in Mr. Pecher, whose extensive knowledge of the semiconductor market will serve him well as he assumes his new role," said Dr. Kurz. "In recent years he has played a pivotal role in ensuring success at the SMT segment – particularly in terms of the latest and future generations of our market-leading EUV technology."
Effective 1 January 2022, the Executive Board of Carl Zeiss AG will thus comprise President and CEO Dr. Karl Lamprecht, Chief Financial Officer Dr. Christian Müller, Head of the ZEISS Consumer Markets segment Dr. Matthias Metz, Head of the ZEISS Industrial Quality & Research segment Dr. Jochen Peter, Head of the ZEISS Medical Technology segment Dr. Markus Weber, and the newly appointed Head of the Semiconductor Manufacturing Technology segment, Mr. Andreas Pecher.
Dr. Ludwin Monz (57) has been at the helm of Carl Zeiss Meditec AG since March 2010, and has been a member of the Executive Board of Carl Zeiss Meditec AG since 2007. Moreover, on 1 January 2014 he was appointed a member of the Executive Board of Carl Zeiss AG. In this role, Dr. Monz is responsible for Corporate Quality Management. He looks after the sales regions of Japan, Spain, France and Turkey. After completing degrees and a doctorate in physics at the University of Mainz, he worked at the National Institute of Standards and Technology in Gaithersburg, USA, and at the GSI Gesellschaft für Schwerionenforschung (Center for Heavy Ion Research) in Darmstadt, as a scientist. He also holds an MBA from Henley Management College in Great Britain. He joined ZEISS in 1994 as a scientist, and two years later became Head of Geodetic Systems Development, before assuming overall responsibility for the business area. In 2000 he moved to ZEISS Medical Technology.
Dr. Markus Weber (48) earned his undergraduate degrees and his doctorate at the universities of Karlsruhe and Ulm. He joined ZEISS Semiconductor Manufacturing Technology in 2002 as a research associate. After holding a series of management positions in a variety of departments, in 2009 Dr. Weber became Head of Advanced Development in the Microsurgery business area of the Medical Technology business group. In 2010 Dr. Weber then became Head of Corporate Research and Technology for the ZEISS Group. 2015 saw him accept a role as Head of the Research Microscopy Solutions SBU, before also becoming Head of the Industrial Quality Research segment in 2018. A year later, in 2019, Dr. Weber was appointed a member of the Executive Board of Carl Zeiss AG. He assumed responsibility for the ZEISS Semiconductor Manufacturing Technology segment, for the Shared Production Unit and for the Korea sales region.
Andreas Pecher (50) studied physics at the University of Würzburg and the University of Texas at Austin. He then earned his Master of Business Administration (MBA) at the Kellogg School of Management and a Master's in Engineering from the McCormick School of Engineering. In 1998, his career led him to work as an engineer in chip production and development at Motorola (now NXP) in Texas, USA. After completing his MBA in 2005, Mr. Pecher worked as a project manager at McKinsey & Company, focusing on high tech and semiconductors. As of 2010, he was Head of the Strategy and Business Development department at solar energy company Renewable Energy Corporation in Oslo and Munich. Then, in 2013, Mr. Pecher joined SMT as Head of Strategic Business Development. 2015 saw him accepting a role as Head of the Semiconductor Metrology Systems strategic business unit (SMS SBU) and, since 2017, he has been Head of the Semiconductor Manufacturing Optics strategic business unit.
ZEISS is an internationally leading technology enterprise operating in the optics and optoelectronics industries. In the previous fiscal year, the ZEISS Group generated annual revenue totaling more than 6.3 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets, and Semiconductor Manufacturing Technology (as of September 30, 2020).
For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Industry 4.0 as well as a strong brand, ZEISS is shaping technological progress and, through its solutions, is extending the horizon of the world of optics and associated areas. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 12% of its revenue in research and development work – ZEISS has a long tradition of high expenditure in these areas. This also represents the company's investment in the future.
With over 34,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company Carl Zeiss AG (as of March 31, 2021).
Further information at www.zeiss.com